Table 7:
Original and Adjusted Cost-Effectiveness Results in the Emergency Department Setting–Standard Clinical Investigations With NT-proBNP Versus Standard Clinical Investigations Alone
| SCI With NT-proBNP Mean (95% CI) | SCI Alone Mean (95% CI) | |
|---|---|---|
| Total Costs per Patient | ||
| 2013 GBP | £2,774 (1,538–4,533) | £2,675 (1,444–4,399) |
| 2019 CAD | $5,714 (3,168–9,337) | $5,510 (2,974–9,061) |
| QALYs | 2.2156 (2.1440–2.2957) | 2.2109 (2.1405–2.2907) |
| Incremental Cost | ||
| 2013 GBP | £98.84 | |
| 2019 CAD | $203.59 | |
| Incremental QALY | 0.0046 | |
| ICER (per QALY gained) | ||
| 2013 GBP | £21,298 (10,754–41,498) | |
| 2019 CAD | $43,869 (22,151–85,477) | |
Abbreviations: CI, confidence interval; NT-proBNP, N-terminal pro–B-type natriuretic peptide; QALY, quality-adjusted life year; SCI, standard clinical investigations.
Note: results presented in this table differ slightly from those presented in the original publication. The 95% CIs around costs and QALYs were not available in the publication, so we contacted the authors54 to obtain the complete probabilistic sensitivity analysis results. The analysis was re-run to generate the 95% CI.